S M T W T F S
 
 
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25
 
26
 
27
 
 
29
 
30
 
31
 
 

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

Tags: option stock
DATE POSTED:January 13, 2020

WALTHAM Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,425,000 shares at the public offering price of $37.00 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Apellis to 10,925,000 shares and increased the amount of gross proceeds, before deducting underwriting discounts and commissions and expenses payable by Apellis, to approximately $404.2 million.

Tags: option stock